ClinicalTrials.gg
RecruitingNCT07492979Nordic-CSPUpdated Jul 28, 2026

Conduction System Pacing vs. Biventricular Pacing for Cardiac Resynchronization Therapy

An interventional study of HIS or LBBB -CRT and Conventional BiV-CRT in Cardiac Resynchronisation Therapy (CRT), Heart Failure and Conduction System Pacing, sponsored by Rigshospitalet, Denmark. Recruiting at 5 sites in 4 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Rigshospitalet, Denmark · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,100
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies in Heart Failure by Rigshospitalet, Denmark — 4 open to participants now, 4 under way, none of them phase 3. Heart Failure · Rigshospitalet, Denmark.

Planned enrollment
3rd of 10
1,100 · median 60
Started
2026
with 1 other
No phase
8 of 17
2 open now
Registered
17th of 17
by date

Among the 17 studies in Heart Failure by Rigshospitalet, Denmark, this one is the 3rd largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2026, is one of 8 with no phase, and was the 17th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

4 of the 17 studies in Heart Failure by Rigshospitalet, Denmark are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Heart Failure by Rigshospitalet, Denmark, or all of them as a file.
02

Study summary

The NORDIC-CSP trial is an investigator-initiated, blinded, nordic RCT aimed at evaluating whether using direct pacing of the HIS bundle (HIS)-pacing or left bundle branch (LBB) pacing is superior to conventional biventricular pacing in reducing the incidence of the composite endpoint of death and non-planned HF hospitalization. The study will be conducted in the 4 CRT-centres in Denmark and 6-8 centres from countries Sweden, Norway and Finland.

Read the detailed description

In this investigator-initiated, blinded, nordic RCT, we will investigate conduction system pacing (CSP) in heart failure (HF) patients. We hypothesized that Cardiac Resynchronization Therapy (CRT) by HIS-pacing or LBB-pacing is superior compared to conventional biventricular (BIV)-CRT in reducing the incidence of the composite endpoint (Death and HF-hospitalization) in patients with symptomatic HF, with LVEF ≤ 35% and indication for CRT.

The Study is a collaboration between CRT centers in the Nordic countries with experience in CSP.

Randomization:

Randomization is conducted electronically using the CRF on the day of device implantation. A computer algorithm will randomly assign patients 1:1 to either the conventional method BIV-CRT or to "the new method" HIS/LBB-CRT.

Randomization will be stratified by the presence of a) true LBBB, b) other bundle branch block (BBB) and c) RV pacing. This will be performed by randomizing in blocks of 10 for LBBB and RV pacing/other bundle branch blocks. Block-randomization is used to ensure that each center includes a similar number of patients for each treatment arm.

The implanting physician is aware of group allocation to provide the correct treatment. Only the implanting physician can access this information in the CRF. The patients and study per-sonnel involved in end-point adjudication as well as all personnel performing imaging analy-sis are blinded to randomization. Follow-up is identical in the two treatment groups. All fol-low-up personnel are blinded to treatment assignment.

Implantation:

The RV electrode is preferentially placed in an RV septal position unless factors related to lead stability, electrical values, and defibrillation vector favor an apical position (at the discretion of the implanting physician). The atrial electrode is positioned at the preference of the implanting physician. With successful implantation of a lead for HIS- or LBB-pacing the physician may prefer to not implant a RV-lead to the septum. In that case, there is no need for a CRT pacemaker and a dual-chamber pacemaker can be implanted instead.

In the HIS-LBB group, CSP is performed according to current recommendations13. The leads allowed to implant in the HIS-LBB position are the ones that have received CE-approval for this indication.

Both HIS-pacing or LBB-pacing can be attempted as first approach at the physician's discretion using available leads both stylet-driven or non-stylet driven and if necessary, guiding from an electrophysiology catheter is used.

HIS-pacing: An approximate ratio of 1:4 between A and V with a clear His deflection is iden-tified and His-capture confirmed. If the threshold for capture of His and the left bundle branches is too high (> 2 V at 1 ms duration) assessed by the operator, the lead should be replaced. If it is not possible to achieve selective or non-selective HIS pacing with bundle branch block correction at a threshold below or equal to 2 V at 1 ms in duration, an attempt to implant the electrode to achieve direct left bundle branch pacing (LBBP) is performed instead.

LBB-pacing: LBB-pacing is performed by moving the sheath a few centimeter further towards the apex of the right ventricle, ensuring contact to the septum. The electrode is screwed into the septum at an angle of -10⁰ to 40⁰ while monitoring current-of-injury (COI), impedance and pacing configuration (gradual emergence of a terminal R-wave in lead V1) until the left bundle branch area is activated and a right-sided bundle branch block pattern is obtained. The operator must attempt to confirm left conduction system capture by identify-ing one or more of the following criteria:

  • Fixation beats (PVC´s identical to the paced QRS-complex,)
  • Identification of LBB-potentials (> 15 ms before sensed QRS) and capture with RBBB-pattern during unipolar pacing on the LBB-lead. (Not in LBBB patients)
  • Transition of QRS patterns during threshold testing:

ns-LBBP to s-LBBP : splitting of EGM and/or V1 RWPT (Rigth wave peak time)¬ by > 10 ms ns-LBBP to LVSP : V6 RWPT¬ by ≥ 15 ms V6 RWPT \< 80 ms (LBBB, IVCD RBBB+fascicular block, wide escape rhythm, asystole) V6 -V1 interpeak interval > 44 ms QRS transition to s-LBBP during programmed stimulation

Or one of the following criteria considered likely to represent left conduction system capture:

V6 RWPT \< 100 ms (LBBB, IVCD, RBBB + fascicular block, wide escape rhythm, asystole V6 -V1 interpeak interval > 33 ms QRS transition to LVSP during programmed stimulation V6 RWPT prolongation by 10-14 ms during threshold test

If the operator is not succesful, after several attempts, obtaining conduction system capture LVseptal capture (LVSP) can be accepted, with identification of a clearly defined R´ in V1. If only deep septal pacing can be obtained the lead can be left in place or removed at the op-erators discretion and an LV-lead has to be implanted to obtain either BIV-CRT or LOT-CRT.

.

Cross-over between intervention arms If neither HIS-pacing nor LBB-pacing is obtainable (none of the abovementioned criteria are met or Left Ventricular septal pacing cannot be obtained), the sheath is switched to a CS sheath instead and an LV electrode is placed as in a conventional CRT procedure. Finally, an atrial electrode is placed if there is not already a usable atrial electrode in place. In all pa-tients, signs of left conduction system capture identified are registered in the CRF.

In the BIV-CRT group, the LV lead is placed in the branch judged to be most suitable, prefer-entially in a posterolateral (2-5 o'clock in the mitral annulus), and mid-ventricular or basal, non-apical position (figure 2), after taking into consideration lead stability, pacing threshold and threshold for phrenic nerve stimulation. In general, multipolar (quadripolar) LV leads are used as first choice but the implanting physician may use a bipolar LV lead if a multipolar lead cannot be implanted. Balloon occlusion venography to visualize the CS and side branches is performed in all patients with a BIV-CRT. Supplementary selective venography may be used to visualize CS branches.

If it is not possible to place a LV -lead due to the anatomical conditions (lack of access to CS, lack of available side bundle branches or only possible to pace in the vena cordis media or vena cordis anterior) or due to unacceptable electrical measurements (best pacing threshold > 4 V at 1,0 msec, or phrenic nerve capture \< 2 x lowest pacing threshold), the sheath is in-stead switched to a HIS sheath and electrode placement to the HIS bundle or LBB area is attempted using available sheaths and guide from electrophysiology catheter as outlined above. Again, it is up to the physician whether HIS- or LBB-pacing is attempted first. If it is not possible to achieve selective or non-selective HIS pacing with bundle branch block cor-rection at a threshold below or equal to 2.5 V at 1 ms in duration, an attempt is done to im-plant the electrode further into the ventricle and achieve direct left bundle branch pacing (LBB-CRT) instead. Finally, an atrial electrode is placed if there is not already a usable atrial lead in place. If it is not possible to place either an LV electrode, a HIS electrode or an elec-trode for LBB pacing, the attending physician must decide whether there is any indication for implantation of a transthoracic LV-lead.

Follow-up:

Clinical- and device check-ups are scheduled after 3-, 6- and 12 months, and annually thereafter according .This means that patients are in fact following the current standard regime after CRT-implantation with similar examinations including standard blood tests. However, in addition the patients will be asked to fill out questionnaires, that is the MLHFQ and PRO Questionnaires at baseline and 12 months. Remote monitoring is established for all pa-tients. Echocardiographic follow-ups are scheduled after 6- and 24 months. A 6MWT is per-formed 6 months. At each follow-up visit, medication is recorded and a ECG-12 is obtained upon patient arrival.

All patients are followed for a minimum of 2 years.

03

Conditions studied

  • Cardiac Resynchronisation Therapy (CRT)
  • Heart Failure
  • Conduction System Pacing

Browse trials for

Keywords

  • Nordic-CSP
  • conduction system pacing
  • His-pacing
  • LBB-pacing
  • Biventricular pacing
  • Cardiac Resynchronization Therapy
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years of age,
  • ≤ 35%,
  • Class II-IV (IV only outpatients),
  • optimized in medical treatment (OMT)

AND one of the following:

. LBBB according to AHA/ACC/HRS Scientific Statement from 2009 and ≥130ms or

  • LBBB-like intraventricular conduction delay (IVCD) > 150ms or RV paced QRS and indication for upgrade to CRT (> 40% RV pacing) OR
  • ≥18 years of age,
  • LVEF ≤ 40 %
  • pacing indicated by AV-block and, thus, expected large percentage of ventricular pacing.

Exclusion criteria

Exclusion Criteria:

  • recent acute myocardial infarction (AMI)
  • coronary artery bypass graft (CABG) (\<3 months)
  • \<2 years, patients in hemodialysis
  • treatment with a cardiac implantable electronic device (CIED) is .
  • Patients are excluded with regards to the MRI sub study if > 35 ml/min, in case or contrast allergy or certain metal implants.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
1,100 participants (estimated)

Study arms

  • Experimental
    LBB/HIS-CRT group

    Procedure: HIS or LBBB -CRT

  • Experimental
    BiV-CRT group

    Procedure: Conventional BiV-CRT

Interventions

  • ProcedureHIS or LBBB -CRT

    HIs pacing og LBB pacing at the implanteres discretion

  • ProcedureConventional BiV-CRT

    An LV-lead in a side-branch of the coronary sinus

06

What researchers measure

Primary outcomes

  1. Patients with a primary end-point

    The primary endpoint is a composite of time to death or first non-planned HF hospitalization. Non-planned HF is defined as an unplanned emergency room visit or admission to hospital due to worsening HF

    Time frame: From enrollment and a minimum of 2 years or the primary outcome has occurred

Secondary outcomes

  1. Patients experiencing device-related complications

    • Device-related complications. Periprocedural complication including electrode reoperation, pneumothorax, hemothorax, pericardial bleeding/tamponade and later complications (after 30 days post implantation) including LV/His electrode reoperation, change of device due to battery depletion and infection requiring extraction.

    Time frame: From baseline until study completion, with a minimum of 2 years.

  2. Death

    All-cause death

    Time frame: From baseline until study completion, with a minimum of 2 years

  3. Non planned HF-hospitalization

    Non-planned HF is defined as an unplanned emergency room visit or admission to hospital due to worsening HF

    Time frame: From baseline until study completion with a minimum of 2 years

  4. Echocardiographic remodelling

    Echocardiographic end-points (re-modelling of the LV measured in mL: LVESV, LVEDV, LVEF). Echocardiographic response after 6 months and 24 months defined as decrease in left ventricular systolic volume ≥ 15% from baseline.

    Time frame: From baseline to 6 months and 24 months

  5. Change in Dyssynchrony

    Change in dyssynchrony parameters myocardial work, longitudinal strain time-to-peak (ms), dyssynchrony patterns (categorized 1-4), apical rocking, septal flash (yes/No)

    Time frame: evaluated at baseline, 6 months, 24 months

  6. Improvement in Clinical response

    Clinical response improvement in NYHA class by ≥ 1 or improvement in 6MWT (≥10% from baseline)" after 12 months.

    Time frame: from baseline to 12 months

  7. Improvement in Six-min walking test.

    Functional response after 6 months defined as an increase in 6-min walking distance (meters) of ≥ 20% of the baseline value

    Time frame: From baseline to 6 months

  8. Neurohormones

    Neurohormones, decline in NT-proBNP after CRT. pg/mL (picograms per milliliter) or ng/L (nanograms per liter)

    Time frame: from baseline to 6 months

  9. Symptomatic response

    defined as a fall in NYHA class of ≥ 1

    Time frame: From baseline to 6 months

  10. Life quality

    Minnesota Living with Heart Failure Qestionnaire. Comparison from baseline to 12 months follow-up in point score (0-105). Number of patients with improvements \> 5 points and above 10 points are determined.

    Time frame: from baseline to follow-up at 12 months

  11. ICD therapy

    ICD-therapy (time to first) of appropriate and inappropriate therapies, ATP or Shock

    Time frame: from baseline to study completion, with a mnimum of 2 years

  12. Ventricular arrythmia

    Time to first VT (\>135/min by ecg or device reading) or VF

    Time frame: from baseline to completion of the study, with a mnimum of 2 years

  13. atrial fibrillation

    time to Persistent atrial fibrillation (\> 7 days) and new-onset atrial fibrilllation (\> 6 hours)

    Time frame: from baseline to completion of the study with a minimum of 2 years

  14. time for implantation

    measured in minutes from skin incision to skin closure

    Time frame: at implantation, from 30 minutes to 300 minutes

  15. x-ray

    • Use of X-ray dosage

    Time frame: at implantation, from 1 minute to 150 minutes

  16. Electrodes

    number of electrodes used

    Time frame: form implantation to completion of the study, a minimum of 2 years

  17. battery longevity

    • Battery longevity: The total battery longevity of each CRT-D was calculated as the sum of the patient's follow-up duration plus the estimated battery longevity remaining at the time of the last follow-up.

    Time frame: from implantation to completion of the study, with a minimum of 2 years

07

Study locations

1 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — not yet a plan for this

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Mar 2031, 56 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 56 months is above that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2026
First posted
Mar 25, 2026
StartActual
Jun 17, 2026
Primary completionEst.
Mar 1, 2031
CompletionEst.
Jul 1, 2031
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07492979
Responsible party
Niels Risum (Md, PhD, Consultant cardiologist and electrophsiologist,, Rigshospitalet, Denmark) — Principal investigator
First posted
Mar 25, 2026
Start date
Jun 17, 2026
Primary completion
Mar 1, 2031 (estimated)
Completion
Jul 1, 2031 (estimated)
Last update
Jul 28, 2026

Study contacts

Niels Risum, MD, PhD
Contact
niels.risum.01@regionh.dk
0045 35456995
Michael Vinther, MD, PhD
Contact
michael.vinther@regionh.dk
0045 35456994
Niels Risum Risum, MD, PhD
principal investigator · Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
michael vinther, MD, PhD
principal investigator · Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Berit Philbert
study chair · Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion